Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $29.74 USD
Change Today +0.78 / 2.69%
Volume 1.8M
EXAS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:20 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

exact sciences corp (EXAS) Snapshot

Open
$29.36
Previous Close
$28.96
Day High
$29.97
Day Low
$29.01
52 Week High
06/25/15 - $32.85
52 Week Low
07/10/14 - $15.01
Market Cap
2.6B
Average Volume 10 Days
2.0M
EPS TTM
$-1.41
Shares Outstanding
88.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXACT SCIENCES CORP (EXAS)

exact sciences corp (EXAS) Related Bloomberg News

View More Bloomberg News

exact sciences corp (EXAS) Related Businessweek News

No Related Businessweek News Found

exact sciences corp (EXAS) Details

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company’s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with MAYO Foundation for Medical Education and Research for developing tests to detect other gastrointestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

236 Employees
Last Reported Date: 02/27/15
Founded in 1995

exact sciences corp (EXAS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $861.1K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $383.1K
Chief Operating Officer, Senior Vice Presiden...
Total Annual Compensation: $638.6K
Chief Science Officer and Senior Vice Preside...
Total Annual Compensation: $518.4K
Compensation as of Fiscal Year 2014.

exact sciences corp (EXAS) Key Developments

Exact Sciences Corp. and The University of Texas MD Anderson Cancer Center Announce Partnership to Develop Screening and Diagnostic Tests for Lung Cancer

Exact Sciences Corp. and The University of Texas MD Anderson Cancer Center announced an agreement to jointly develop and commercialize blood-based screening and diagnostic tests for the early detection of lung cancer. This collaboration seeks to build upon MD Anderson’s extensive research into predictive biomarkers for lung cancer and Exact Sciences’ successful development and commercialization of Cologuard®, the FDA-approved, non-invasive stool-based DNA colon cancer screening test. The two groups plan to develop a groundbreaking new blood test that targets biomarkers associated with lung cancer. The collaboration specifically aims at developing a blood-based lung cancer screening test to determine the need for low-dose computed tomography (LDCT). This test would offer the opportunity to screen nearly 11 million Americans considered high-risk smokers and former smokers. The partnership is also aimed at developing a diagnostic test to determine the malignant status of nodules found through LDCT screening. This test would be valuable to nearly four million Americans diagnosed with lung nodules each year.

Exact Sciences Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:00 AM

Exact Sciences Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Kevin T. Conroy, Chairman of the Board, Chief Executive Officer and President.

Exact Sciences Corporation Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 10:40 AM

Exact Sciences Corporation Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 10:40 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: Kevin T. Conroy, Chairman of the Board, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXAS:US $29.74 USD +0.78

EXAS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curis Inc $3.31 USD +0.19
Delcath Systems Inc $0.96 USD -0.0015
MELA Sciences Inc $1.15 USD 0.00
Navidea Biopharmaceuticals Inc $1.61 USD -0.02
ZIOPHARM Oncology Inc $12.00 USD +0.46
View Industry Companies
 

Industry Analysis

EXAS

Industry Average

Valuation EXAS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 445.0x
Price/Book 9.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 403.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXACT SCIENCES CORP, please visit www.exactsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.